Otsuka Pharmaceutical Co., Ltd.
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
Lupus Nephritis
Voclosporin (LUPKYNIS)
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 400 participants |
| Official Title : | LUPKYNIS Drug-use Results Survey |
| Actual Study Start Date : | 2025-09-17 |
| Estimated Primary Completion Date : | 2031-06-30 |
| Estimated Study Completion Date : | 2032-06-30 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 15 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Pharmacovigilance Department
Osaka, Osaka, Japan, 540-0021